JNJ's Janssen closer to new Invega OK

Diversified health-care products maker Johnson & Johnson on Friday said its Janssen-Cilag unit's schizophrenia drug candidate Invega received a positive recommendation from European regulators.

The Committee for Human Medicinal Products in the European Union gave the drug a positive recommendation for approval. The drug will likely be approved in the European Union based on the positive recommendation. Also Friday, the U.S. Food and Drug Administration approved the drug as a long-term treatment for schizophrenia. It had already been approved as a short-term treatment.

READ MORE @ Hemscott.com